BG98933A - Cooled and atomized nabumetone - Google Patents

Cooled and atomized nabumetone

Info

Publication number
BG98933A
BG98933A BG98933A BG9893394A BG98933A BG 98933 A BG98933 A BG 98933A BG 98933 A BG98933 A BG 98933A BG 9893394 A BG9893394 A BG 9893394A BG 98933 A BG98933 A BG 98933A
Authority
BG
Bulgaria
Prior art keywords
nabumetone
atomized
cooled
far
produced
Prior art date
Application number
BG98933A
Other languages
Bulgarian (bg)
English (en)
Inventor
Graham LEONARD
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of BG98933A publication Critical patent/BG98933A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/255Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coating By Spraying Or Casting (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Catching Or Destruction (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Road Signs Or Road Markings (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Freezing, Cooling And Drying Of Foods (AREA)
BG98933A 1992-01-29 1994-07-28 Cooled and atomized nabumetone BG98933A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929201857A GB9201857D0 (en) 1992-01-29 1992-01-29 Novel compound
PCT/GB1993/000145 WO1993014747A1 (en) 1992-01-29 1993-01-22 Spray-chilled nabumetone

Publications (1)

Publication Number Publication Date
BG98933A true BG98933A (en) 1995-07-28

Family

ID=10709436

Family Applications (1)

Application Number Title Priority Date Filing Date
BG98933A BG98933A (en) 1992-01-29 1994-07-28 Cooled and atomized nabumetone

Country Status (24)

Country Link
US (1) US5539000A (xx)
EP (1) EP0624087B1 (xx)
JP (1) JPH07503245A (xx)
KR (1) KR950700056A (xx)
CN (1) CN1079954A (xx)
AT (1) ATE150298T1 (xx)
AU (1) AU3362693A (xx)
BG (1) BG98933A (xx)
BR (1) BR9305674A (xx)
CA (1) CA2129027A1 (xx)
CZ (1) CZ182894A3 (xx)
DE (1) DE69309037T2 (xx)
DK (1) DK0624087T3 (xx)
ES (1) ES2099419T3 (xx)
FI (1) FI943550A (xx)
GB (1) GB9201857D0 (xx)
GR (1) GR3023142T3 (xx)
HU (1) HUT67462A (xx)
IL (1) IL104526A0 (xx)
MX (1) MX9300430A (xx)
NO (1) NO942813D0 (xx)
SK (1) SK91694A3 (xx)
WO (1) WO1993014747A1 (xx)
ZA (1) ZA93577B (xx)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB9920148D0 (en) * 1999-08-25 1999-10-27 Smithkline Beecham Plc Novel composition
US6436990B1 (en) 1999-10-27 2002-08-20 Nobex Corporation 6-methoxy-2-naphthylacetic acid prodrugs
US6552078B2 (en) 1999-10-27 2003-04-22 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
TWI262791B (en) 1999-10-27 2006-10-01 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
US20020132010A1 (en) * 2000-12-22 2002-09-19 Yihong Qui Divalproex sodium dosage forms and a process for their production
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US20060083791A1 (en) * 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
BRPI0416534A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc composições multiparticuladas com estabilidade melhorada
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
PT1691787E (pt) * 2003-12-04 2008-09-02 Pfizer Prod Inc Método de formação de multipartículas farmacêuticas
BRPI0417348A (pt) * 2003-12-04 2007-03-13 Pfizer Prod Inc processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
WO2005053653A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
BRPI0417338A (pt) * 2003-12-04 2007-04-17 Pfizer Prod Inc formas de dosagem de azitromicina multiparticulada por processos a base de lìquido
CA2583548A1 (en) * 2004-10-15 2006-04-27 Altairnano, Inc. Phosphate binder with reduced pill burden
US20080058250A1 (en) * 2005-08-17 2008-03-06 Allison Wren Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US8436051B2 (en) * 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) * 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US8961917B2 (en) 2010-05-12 2015-02-24 Spectrum Pharmaceuticals, Inc. Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
EP3544614A4 (en) 2016-11-28 2020-08-05 Lipocine Inc. ORAL TESTOSTERONE UNDECANOATE THERAPY

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1474377A (en) 1973-09-11 1977-05-25 Beecham Group Ltd Naphthalene derivatives
US4420639C1 (en) * 1973-09-11 2001-08-21 Beecham Group Ltd Aromatic compounds
US4086346A (en) 1974-04-06 1978-04-25 Bayer Aktiengesellschaft Preparation of melt-sprayed spherical phenacetin granules
DE3833446A1 (de) * 1988-10-01 1990-04-05 Hoechst Ag Verfahren zur herstellung von arzneimittelwirkstoff-partikeln mit verbesserten fliess-, lager- und formulierungseigenschaften sowie arzneimittel, die diese arzneimittelwirkstoff-partikeln enthalten

Also Published As

Publication number Publication date
DE69309037D1 (de) 1997-04-24
NO942813L (no) 1994-07-28
GB9201857D0 (en) 1992-03-18
EP0624087A1 (en) 1994-11-17
WO1993014747A1 (en) 1993-08-05
KR950700056A (ko) 1995-01-16
EP0624087B1 (en) 1997-03-19
AU3362693A (en) 1993-09-01
IL104526A0 (en) 1993-05-13
ATE150298T1 (de) 1997-04-15
JPH07503245A (ja) 1995-04-06
FI943550A0 (fi) 1994-07-28
DE69309037T2 (de) 1997-07-24
CA2129027A1 (en) 1993-08-05
CN1079954A (zh) 1993-12-29
GR3023142T3 (en) 1997-07-30
MX9300430A (es) 1994-08-31
NO942813D0 (no) 1994-07-28
HU9402221D0 (en) 1994-09-28
SK91694A3 (en) 1995-03-08
ES2099419T3 (es) 1997-05-16
FI943550A (fi) 1994-07-28
BR9305674A (pt) 2005-01-11
DK0624087T3 (da) 1997-09-01
CZ182894A3 (en) 1995-02-15
US5539000A (en) 1996-07-23
ZA93577B (en) 1994-01-13
HUT67462A (en) 1995-04-28

Similar Documents

Publication Publication Date Title
BG98933A (en) Cooled and atomized nabumetone
AP1450A (en) Solid oral dosage form comprising a combination of metformin and glibenclamide.
EP0494972A4 (en) Effervescent dosage form and method of administering same
TW272195B (xx)
CZ44195A3 (en) Pharmaceutical preparation containing il-4 and/or il-10 or antibodies against il-4 and il-10, process of its preparation and use
GEP20074251B (en) N-oxycarbonyl substituted 5'- deoxy-5-fluorocytidines
IL106326A0 (en) Peptides, their production and pharmaceutical compositions containing them
MY102365A (en) Di-t-butylphenol compounds.
HU9403323D0 (en) 4-mercaptioacetylamino-[2] benzazepinone(3) derivatives, and use as enkephalinase inhibitors
ES2191174T3 (es) (-)hidroxicitrato de magnesio, procedimiento de preparacion, aplicaciones y composiciones principalmente farmaceuticas que lo contienen.
IL104999A0 (en) Substituted phenylacetamides,their preparation and pharmaceutical compositions containing them
MY128260A (en) Cyclopentane-and-pentene-b-amino acids
DE69311541T2 (de) Kosmetische oder pharmazeutische zusammensetzungen zur topischen anwendung die deacylierten glycerophospholipide enthalten
IL105000A0 (en) Imidazolyl-substituted phenylacetamides,their preparation and pharmaceutical compositions containing them
BG100248A (en) Squalene synthetase inhibitors
EP0638080A4 (en) PYRIMIDINE 7-BISUBSTITUEE-METHYL-4-OXO-3H -, 5H --PYRROLO 3,2-d -], PHARMACEUTICAL USE AND COMPOSITIONS CONTAINING SAID PYRIMIDINE.
EP0461261A4 (en) MIXTURE OF OLIGOPEPTIDES AND PREPARATION CONTAINING SAME.
MD970269A (en) Clavulanates
BG101849A (en) Bicyclic tachyquinine antagonists, their preparation and use in pharmaceutical compositions
HUT65134A (en) Process for the production of carbapenem-derivatives condensed with cyclohexan-ring and of pharmaceutical compositions containing it
HUT65768A (en) 17-beta-substituted 4-aza-androstane-derivatives and pharmaceutical compositions containing them and process for the production thereof
IT1199619B (it) Vernici additivate
GB2252729B (en) Vitamin and/or mineral containing pharmaceutical compositions
HUT73481A (en) Tropane-derivates having analgesic and nootropic effect and pharmaceutical compositions containing the same
IL94942A0 (en) Pharmaceutical compositions containing retinoids for the treatment and prophylaxis of disorders of the immune system